References
- Mother R J, Schwartz L, Law T M. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1950–1957; 8, 1995
- Minasian L M, Motzer RJ., Gluck L. Interferon alfa-2u in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 7: 1368–1375
- Motzer R J, Murphy B A, Mazumdar M. Randomized phase III trial of interferon alfa-2A (IFN) versus IFN plus 13-cis-retinoic Acid (CRA) in patients (pts) with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1999; 18: 1271
- Rosenberg S A, Lotze M T, Yang J C. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622–632
- Figlin R A, Thompson J A, Bukowsi R M. Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal carcinoma. J Clin Oncol 1999; 17: 2521–2529
- Negrier S, Escudier B, Lasset C. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272–1278
- Escudier B, Chevreau C, Lasset C. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon-α after failure of a first treatment. J Clin Oncol 1999; 17: 2039–2043